{
    "clinical_study": {
        "@rank": "164663", 
        "arm_group": [
            {
                "arm_group_label": "rifaximin and pentoxifylline", 
                "arm_group_type": "Experimental", 
                "description": "Tab Rifaximin 400 mg thrice daily + Pentoxifylline 400 mg thrice daily for 12 weeks"
            }, 
            {
                "arm_group_label": "pentoxifylline and placebo", 
                "arm_group_type": "Active Comparator", 
                "description": "Tab Pentoxifylline 400 mg thrice daily + Placebo thrice daily for 12 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "-  The study will be a prospective open labelled double blinded randomized controlled\n           study.\n\n        -  The study will be conducted on patients admitted to Department of Hepatology from 2012\n           to 2014 at Institute of Liver and Biliary Sciences, New Delhi\n\n        -  Patients diagnosed as having clinical or subclinical hepatopulmonary syndrome will be\n           started on oral pentoxifylline therapy 400 mg thrice daily for 12 weeks.\n\n        -  Patients not responding to this therapy will be given divided into 2 arms with one arm\n           receiving additional Tab Rifaximin 400 mg thrice daily or placebo for 12 weeks."
        }, 
        "brief_title": "Efficacy of Pentoxifylline and Rifaximin Combination in Pentoxifylline Refractory Clinical and Subclinical Hepatopulmonary Syndrome", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Hepatopulmonary Syndrome", 
        "condition_browse": {
            "mesh_term": "Hepatopulmonary Syndrome"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Evidence of portal hypertension (esophagogastric varices or portal hypertensive\n             gastropathy identified on esophagogastroduodenoscopy, and/or varices seen on\n             computerized tomography scan or ultrasound, and/or splenomegaly with no other\n             explanation, and/or ascites with no other explanation)\n\n          2. Intrapulmonary vascular dilatations (IPVDs) diagnosed on contrast echocardiogram (CE)\n\n          3. AaDO2 > 15 mm Hg on standing room air arterial blood gas (ABG)\n\n          4. Ability and willingness to give informed consent\n\n        Exclusion Criteria:\n\n          -  Age < 18 or > 64\n\n          -  Intrinsic significant cardiopulmonary disease\n\n          -  Inability to perform pulmonary function tests\n\n          -  Moderate to severe Pulmonary hypertension\n\n          -  Advanced hepatic encephalopathy\n\n          -  Inadequate echocardiographic window to allow for accurate transthoracic contrast\n             echocardiography\n\n          -  Antibiotic use within the last one month\n\n          -  Listed for liver transplant in next 4 weeks\n\n          -  Current use of exogenous nitrates\n\n          -  Active bacterial infections\n\n          -  Known malignancy\n\n          -  Known intolerance to Pentoxifylline or rifaximin"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "64 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "80", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 29, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01676597", 
            "org_study_id": "ILBS-HPS-01"
        }, 
        "intervention": [
            {
                "arm_group_label": "pentoxifylline and placebo", 
                "description": "Tab Rifaximin 400 mg thrice daily + Pentoxifylline 400 mg thrice daily for 12 weeks", 
                "intervention_name": "pentoxifylline and rifaximin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "rifaximin and pentoxifylline", 
                "description": "Tab Pentoxifylline 400 mg thrice daily + Placebo thrice daily for 12 weeks", 
                "intervention_name": "Pentoxifylline and placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Pentoxifylline", 
                "Rifaximin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "December 16, 2013", 
        "location": {
            "contact": {
                "email": "naveenilbsdelhi@gmail.com", 
                "last_name": "Dr Naveen , MD", 
                "phone": "011-46300000"
            }, 
            "contact_backup": {
                "email": "bhardwaj.ankit3@gmail.com", 
                "last_name": "Dr Ankit Bhardwaj", 
                "phone": "011-46300000", 
                "phone_ext": "1032"
            }, 
            "facility": {
                "address": {
                    "city": "New Delhi", 
                    "country": "India", 
                    "state": "Delhi", 
                    "zip": "110070"
                }, 
                "name": "Institute of Liver and Biliary Sciences"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "India"
        }, 
        "number_of_arms": "2", 
        "overall_contact": {
            "email": "naveenilbsdelhi@gmail.com", 
            "last_name": "Dr Naveen Kumar, MD", 
            "phone": "011-46300000"
        }, 
        "overall_contact_backup": {
            "email": "bhardwaj.ankit3@gmail.com", 
            "last_name": "Dr Ankit Bhardwaj", 
            "phone": "011-46300000", 
            "phone_ext": "1032"
        }, 
        "overall_official": {
            "affiliation": "Institute of Liver and Biliary Sciences", 
            "last_name": "Dr Naveen Kumar, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "India: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Complete response after 3 months of treatment", 
            "safety_issue": "No", 
            "time_frame": "3 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01676597"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Development of serious adverse effects leading to withdrawal of the drug", 
            "safety_issue": "Yes", 
            "time_frame": "3 months"
        }, 
        "source": "Institute of Liver and Biliary Sciences, India", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Institute of Liver and Biliary Sciences, India", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2012"
    }
}